Arcellx, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACLX Nasdaq 2836 www.arcellx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcellx, Inc.

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock? - Jan 16th, 2025 1:33 pm
Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock? - Jan 7th, 2025 9:14 am
Arcellx Stock Earns 82 Relative Strength Rating - Dec 27th, 2024 7:09 pm
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma - Dec 11th, 2024 2:00 am
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. - Dec 9th, 2024 9:22 pm
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Dec 9th, 2024 12:50 pm
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition - Dec 9th, 2024 4:00 am
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - Nov 13th, 2024 5:00 pm
Arcellx Third Quarter 2024 Earnings: Misses Expectations - Nov 9th, 2024 2:55 pm
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - Nov 8th, 2024 2:40 pm
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Nov 7th, 2024 10:15 pm
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - Nov 7th, 2024 9:00 pm
Arcellx price target raised to $106 from $81 at Morgan Stanley - Nov 7th, 2024 11:41 am
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - Nov 7th, 2024 11:27 am
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - Nov 5th, 2024 2:00 pm
Cancer cell therapy from Arcellx, Gilead shows promise in early data - Nov 5th, 2024 12:19 pm
Arcellx (ACLX) Surged in Q3. Here’s Why - Nov 1st, 2024 2:43 am
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Oct 9th, 2024 1:40 pm
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates - Aug 8th, 2024 9:25 pm
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates - Aug 8th, 2024 8:00 pm